Mereo BioPharma (MREO) Research & Development (2023 - 2026)

Mereo BioPharma (MREO) has reported Research & Development for 4 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.

• Quarterly Research & Development rose 20.79% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.6 million (down 10.95% YoY) and the FY2025 annual result came in at $17.8 million, down 15.12% from the prior year.
• Research & Development grew to $4.7 million in Q1 2026 per MREO's latest filing, from $4.2 million in the prior quarter.
• Over the last five years, Research & Development for MREO reached as high as $8.8 million in Q4 2024 and fell as low as $3.2 million in Q3 2024.
• A 4-year average of $4.7 million and a median of $4.3 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development surged 83.62% — and 2025, when it tumbled 52.47%.
• Year by year, Research & Development stood at $4.8 million in 2023, then jumped by 83.62% to $8.8 million in 2024, then slumped by 52.47% to $4.2 million in 2025, then climbed by 13.21% to $4.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $4.7 million, $4.2 million, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.